Sun Pharma: Sustained traction in speciality to be a re-rating driver

Trading Calls - Equity F&O

Sun Pharma’s India business is expected to gain traction as sub-chronic and acute therapies pick up with the opening up of clinics/OPDs. This is likely to be fully backed by the field force where the expansion has recently been completed

Anubhav Sahu